Fresenius SE & Co KGaA (FRE) - Financial and Strategic SWOT Analysis Review

May 2021 | 70 pages | ID: FE9EB258879DEN
GlobalData

Abstracts

Fresenius SE & Co KGaA (FRE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Fresenius SE & Co KGaA (Fresenius) is a global healthcare group that offers products and services for dialysis, hospitals, and outpatient treatment. It provides various dialysis services through its own clinics and sells products to other dialysis service providers. Its major products and services include machines for hemodialysis, acute dialysis and peritoneal dialysis; solutions for infusion therapy; dialysis care services; liver support therapy services; and provision projects and services for hospitals and other health care facilities. It also operates and manages acute care and postacute care hospitals in Germany through Helios Kliniken Group. It has major manufacturing plants in the US, Germany, China, Sweden and Japan. Fresenius conducts operations in Asia-Pacific, Europe, Africa and the Americas. The company is headquartered in Bad Homburg, Hessen, Germany.

Fresenius SE & Co KGaA Key Recent Developments

Feb 23,2021: Fresenius achieves 2020 targets and expects healthy business development in 2021 despite ongoing COVID-19 impact
Feb 01,2021: Fresenius achieves FY/20 guidance demonstrating resilience amid the COVID-19 pandemic – Targets healthy sales growth and at least broadly stable net income year over year in FY/21
Feb 01,2021: Fresenius Medical Care anticipates significant negative impact on 2021 net income from accelerated COVID-19 related excess mortality of dialysis patients; confirms mid-term targets
Dec 11,2020: Fresenius improves in climate ranking
Nov 16,2020: Fresenius Medical Care included for 11th time in Dow Jones Sustainability Index

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Fresenius SE & Co KGaA - Key Facts
Fresenius SE & Co KGaA - Key Employees
Fresenius SE & Co KGaA - Key Employee Biographies
Fresenius SE & Co KGaA - Major Products and Services
Fresenius SE & Co KGaA - History
Fresenius SE & Co KGaA - Company Statement
Fresenius SE & Co KGaA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Fresenius SE & Co KGaA - Business Description
Business Segment: Fresenius Helios
Overview
Performance
Key Stats
Business Segment: Fresenius Kabi
Overview
Performance
Business Segment: Fresenius Medical Care
Overview
Performance
Business Segment: Fresenius Vamed
Overview
Performance
Key Stats
Geographical Segment: Africa
Performance
Geographical Segment: Asia-Pacific
Performance
Overview
Geographical Segment: Europe
Performance
Overview
Geographical Segment: Latin America
Performance
Geographical Segment: North America
Performance
R&D Overview
Fresenius SE & Co KGaA - Corporate Strategy
Fresenius SE & Co KGaA - SWOT Analysis
SWOT Analysis - Overview
Fresenius SE & Co KGaA - Strengths
Fresenius SE & Co KGaA - Weaknesses
Fresenius SE & Co KGaA - Opportunities
Fresenius SE & Co KGaA - Threats
Fresenius SE & Co KGaA - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Fresenius SE & Co KGaA, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 23, 2021: Fresenius achieves 2020 targets and expects healthy business development in 2021 despite ongoing COVID-19 impact
Feb 01, 2021: Fresenius achieves FY/20 guidance demonstrating resilience amid the COVID-19 pandemic – Targets healthy sales growth and at least broadly stable net income year over year in FY/21
Feb 01, 2021: Fresenius Medical Care anticipates significant negative impact on 2021 net income from accelerated COVID-19 related excess mortality of dialysis patients; confirms mid-term targets
Dec 11, 2020: Fresenius improves in climate ranking
Nov 16, 2020: Fresenius Medical Care included for 11th time in Dow Jones Sustainability Index
Oct 09, 2020: Fresenius Helios expands reporting on quality standards
Sep 14, 2020: 2021 DRG inflator for German hospitals set at 2.53%
Aug 28, 2020: Fresenius: Annual General Meeting: Stable business model proves its strength; 27th consecutive dividend increase approved
Aug 18, 2020: Fresenius Kabi introduces RFID smart labels for a range of essential medications
Jul 30, 2020: Solid H1 results in light of significant contributions to combat COVID-19 – Accelerated earnings growth expected in H2 – New FY/20 guidance incorporates estimated COVID-19 effects

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Fresenius SE & Co KGaA, Key Facts
Fresenius SE & Co KGaA, Key Employees
Fresenius SE & Co KGaA, Key Employee Biographies
Fresenius SE & Co KGaA, Major Products and Services
Fresenius SE & Co KGaA, History
Fresenius SE & Co KGaA, Other Locations
Fresenius SE & Co KGaA, Subsidiaries
Fresenius SE & Co KGaA, Key Competitors
Fresenius SE & Co KGaA, Ratios based on current share price
Fresenius SE & Co KGaA, Annual Ratios
Fresenius SE & Co KGaA, Annual Ratios (Cont...1)
Fresenius SE & Co KGaA, Annual Ratios (Cont...2)
Fresenius SE & Co KGaA, Interim Ratios
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Fresenius SE & Co KGaA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Fresenius SE & Co KGaA, Performance Chart (2016 - 2020)
Fresenius SE & Co KGaA, Ratio Charts
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021